← Leaderboards
Katrin I Andreasson
Johns Hopkins University
$26,152,030
Attributed
$29,224,129
Total exposure
19
Grants
16
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.5M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$29,224,129 · 19
By mechanism
R01$16,407,886 · 8
RF1$9,677,897 · 5
R21$2,665,048 · 5
R56$473,298 · 1
Top collaborators
- Kathleen Lombard Poston6 shared
- Olivier Boutaud2 shared
- Michelle Louise James2 shared
- Tarik F Massoud2 shared
- Thomas J Montine2 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Luis Andres Garza$9,883,093
- William Ramses Bishai$43,237,711
- Peter A Calabresi$20,846,075
- Michael S Yu$4,793,134
- Sabra L Klein$13,115,675
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposBrainGeneticInflammatoryInflammationPathway InteractionsDinoprostoneMediatingCellsSignal TransductionS DiseaseResponseReceptorMicrogliaInflammatory ResponseIn VivoMacrophageInjuryNeuronsSignal PathwayMouse ModelCerebral IschemiaPtgs2 GeneAnti-Inflammatory Agents
Grant awards (56)
Reprogramming myeloid cell metabolism to prevent cognitive aging and Alzheimer's Disease$602,463
R01 · FY2025 · AG · contact PI
The role of peripheral versus brain myeloid immunity in the cognitive decline of aging and Alzheimer's disease$572,148
R01 · FY2025 · AG · contact PI
Reprogramming myeloid cell metabolism to prevent cognitive aging and Alzheimer's Disease$614,758
R01 · FY2024 · AG · contact PI
Metabolic mechanisms of cognitive decline in aging and AD mediated by inflammatory PGE2 signaling$1,923,592
RF1 · FY2023 · AG · contact PI
The impact of early Tau pathology on cognitive progression and neuropsychiatric symptoms in Parkinson's disease$722,964
R01 · FY2023 · NS
The role of peripheral versus brain myeloid immunity in the cognitive decline of aging and Alzheimer's disease$1,749,426
RF1 · FY2022 · AG · contact PI
The impact of early Tau pathology on cognitive progression and neuropsychiatric symptoms in Parkinson's disease$746,957
R01 · FY2022 · NS
Reprogramming myeloid cell metabolism to prevent cognitive aging and Alzheimer's Disease$1,913,000
RF1 · FY2021 · AG · contact PI
The impact of early Tau pathology on cognitive progression and neuropsychiatric symptoms in Parkinson's disease$746,957
R01 · FY2021 · NS
Modulating the post-stroke inflammatory response to improve outcome in models of cerebral ischemia$484,396
R01 · FY2021 · NS · contact PI
The impact of early Tau pathology on cognitive progression and neuropsychiatric symptoms in Parkinson's disease$392,910
R01 · FY2021 · NS
The impact of early Tau pathology on cognitive progression and neuropsychiatric symptoms in Parkinson's disease$768,085
R01 · FY2020 · NS
Modulating the post-stroke inflammatory response to improve outcome in models of cerebral ischemia$518,800
R01 · FY2020 · NS · contact PI
Modulating the post-stroke inflammatory response to improve outcome in models of cerebral ischemia$34,010
R01 · FY2020 · NS · contact PI
The impact of early Tau pathology on cognitive progression and neuropsychiatric symptoms in Parkinson's disease$781,525
R01 · FY2019 · NS
Modulating the post-stroke inflammatory response to improve outcome in models of cerebral ischemia$382,667
R01 · FY2019 · NS · contact PI
Tracking the invaders in multiple sclerosis: Highly specific TREM1-targeted PET imaging of toxic infiltrating myeloid cells and early treatment response.$234,910
R21 · FY2019 · NS
Targeting the kynurenine pathway in Alzheimer's disease$480,018
R01 · FY2018 · AG · contact PI
Modulating the post-stroke inflammatory response to improve outcome in models of cerebral ischemia$382,574
R01 · FY2018 · NS · contact PI
Tracking the invaders in multiple sclerosis: Highly specific TREM1-targeted PET imaging of toxic infiltrating myeloid cells and early treatment response.$195,781
R21 · FY2018 · NS
Regulation of immune cell metabolism in aging and Alzheimer's disease: role of the kynurenine pathway$2,042,865
RF1 · FY2017 · AG · contact PI
Targeting the kynurenine pathway in Alzheimer's disease$478,770
R01 · FY2017 · AG · contact PI
Modulating the post-stroke inflammatory response to improve outcome in models of cerebral ischemia$473,298
R56 · FY2017 · NS · contact PI
The role of TREM1 signaling in the development of Alzheimerâs disease$2,049,014
RF1 · FY2016 · AG · contact PI
Targeting the kynurenine pathway in Alzheimer's disease$478,136
R01 · FY2016 · AG · contact PI
Targeting the kynurenine pathway in Alzheimer's disease$462,892
R01 · FY2015 · AG · contact PI
Protective Prostaglandin Receptors in Cerebral Ischemia$359,826
R01 · FY2015 · NS · contact PI
Microglial and macrophage PGE2 signaling in post-stroke inflammation$244,513
R21 · FY2015 · NS · contact PI
Targeting the kynurenine pathway in Alzheimer's disease$506,738
R01 · FY2014 · AG · contact PI
Protective Prostaglandin Receptors in Cerebral Ischemia$355,900
R01 · FY2014 · NS · contact PI
Microglial and macrophage PGE2 signaling in post-stroke inflammation$204,149
R21 · FY2014 · NS · contact PI
Protective Prostaglandin Receptors in Cerebral Ischemia$346,597
R01 · FY2013 · NS · contact PI
Prostanoid signaling and inflammation in aging and Alzheimer's disease$300,391
R01 · FY2013 · AG · contact PI
Targeting protein adduction by reactive aldehydes in Alzheimer's disease$226,951
R21 · FY2013 · AG · contact PI
Protective Prostaglandin Receptors in Cerebral Ischemia$346,785
R01 · FY2012 · NS · contact PI
Prostanoid signaling and inflammation in aging and Alzheimer's disease$317,653
R01 · FY2012 · AG · contact PI
Targeting protein adduction by reactive aldehydes in Alzheimer's disease$213,964
R21 · FY2012 · AG · contact PI
Protective Prostaglandin Receptors in Cerebral Ischemia$346,542
R01 · FY2011 · NS · contact PI
Prostanoid signaling and inflammation in aging and Alzheimer's disease$317,440
R01 · FY2011 · AG · contact PI
Protective PGE2 receptors as therapeutic targets in cerebral ischemia.$204,905
R21 · FY2011 · NS · contact PI
Protective prostaglandin receptors in cerebral ischemia$403,406
R01 · FY2010 · NS · contact PI
Prostanoid signaling and inflammation in aging and Alzheimer's disease$330,041
R01 · FY2010 · AG · contact PI
Protective PGE2 receptors as therapeutic targets in cerebral ischemia.$247,837
R21 · FY2010 · NS · contact PI
Validation of the PGE2 EP4 receptor as a therapeutic target in AD$166,111
R21 · FY2010 · AG · contact PI
Validation of the PGE2 EP4 receptor as a therapeutic target in AD$524,371
R21 · FY2009 · AG · contact PI
Protective prostaglandin receptors in cerebral ischemia$407,059
R01 · FY2009 · NS · contact PI
Prostanoid signaling and inflammation in aging and Alzheimer's disease$333,168
R01 · FY2009 · AG · contact PI
Validation of the PGE2 EP4 receptor as a therapeutic target in AD$201,556
R21 · FY2009 · AG · contact PI
Mechanism of COX-2 mediated injury in stroke$278,715
R01 · FY2007 · NS · contact PI
Mechanism of COX-2 mediated injury in stroke$295,368
R01 · FY2006 · NS · contact PI
Mechanism of COX-2 mediated injury in stroke$264,666
R01 · FY2005 · NS
Mechanism of COX-2 mediated injury in stroke$264,666
R01 · FY2004 · NS
MODELS OF ALZHEIMER'S DISEASE$122,625
R01 · FY2003 · AG
MODELS OF ALZHEIMER'S DISEASE$290,371
R01 · FY2002 · AG
MODELS OF ALZHEIMER'S DISEASE$281,915
R01 · FY2001 · AG
MODELS OF ALZHEIMER'S DISEASE$286,984
R01 · FY2000 · AG